Corbus Pharmaceuticals Holdings Inc Dossier - Source-backed chat

Corbus Pharmaceuticals Holdings Inc

CRBPNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)2.06

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $6.34Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $122.6M

Enterprise Value $99.3M

Shares Outstanding 20.2M diluted

Next Earnings Date31 Mar 2027

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Corbus Pharmaceuticals is transitioning from an early clinical-stage biotech to a registrational-stage innovator with two high-potential assets: CRB-701, a next-generation Nectin-4 antibody-drug conjugate (ADC) with robust activity in HPV-driven cancers, and CRB-913, a peripherally restricted oral CB1 inverse agonist targeting obesity. With broad FDA alignment on registrational pathways and a cash runway extending into 2028, Corbus offers an asymmetric risk-reward profile ahead of major clinical catalysts in late 2026.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets10 analysts · as of 18 Aug 2026

Low · most bearish analyst$17.25

Mean target$34.53

High · most bullish analyst$48.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$5.4920%

CRB-701's registrational trials face severe enrollment delays or competitive pressure from emerging ADCs. CRB-913's Phase 1b data shows muted weight loss or unexpected neuropsychiatric side effects (e.g., anxiety, irritability) typical of historical CB1 blockers, leading to program discontinuation and a steep valuation contraction back to cash value.

Base CaseCentral scenario

$30.0050%

CRB-701 successfully initiates its registrational TEMPO-1 trial in 2L OPSCC with steady enrollment, supported by its FDA Fast Track designation. CRB-913's Phase 1b data confirms steady, safe weight loss, validating its peripheral restriction and supporting progression into Phase 2. The company's cash runway remains secure into 2028, minimizing near-term dilution risk.

Bull CaseUpside scenario

$54.0030%

CRB-701 demonstrates superior durability and safety compared to first-generation Nectin-4 ADCs, capturing significant market share in second-line head and neck (OPSCC) and cervical cancers. Simultaneously, CRB-913's Phase 1b CANYON-1 trial delivers highly competitive 12-week weight loss with a clean neuropsychiatric and GI safety profile, positioning it as a premier non-GLP-1 oral weight management option and attracting a major pharmaceutical partnership.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Differentiated Nectin-4 ADC (CRB-701) showing high response rates (42.9% confirmed ORR) and lower toxicity (low peripheral neuropathy and skin rash) compared to Padcev.
Orthogonal oral obesity mechanism (CRB-913) targeting CB1 with peripheral restriction to avoid central nervous system side effects.
Strong balance sheet with $138.2M in cash as of Q1 2026, providing a runway into 2028 and covering key registrational milestones.
Broad FDA alignment on randomized registrational study designs for CRB-701 in HNSCC and cervical cancer.

Key Investment Risks

High clinical and regulatory binary risk associated with upcoming Phase 1b obesity data and registrational oncology trials.
Historical class-wide safety concerns for CB1 inverse agonists regarding neuropsychiatric adverse events.
Intense competition in both the ADC oncology space and the rapidly evolving obesity therapeutic market.

Thesis Invalidation Triggers

Failure of CRB-913 to show competitive weight loss or any signal of severe neuropsychiatric adverse events in the CANYON-1 trial.
Inability to initiate or enroll the CRB-701 TEMPO-1 registrational trial on the projected timeline.
Significant safety signals (e.g., severe ocular or skin toxicities) emerging in larger CRB-701 patient cohorts.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.